Skip to main content
. Author manuscript; available in PMC: 2021 Jun 23.
Published in final edited form as: ACS Nano. 2020 May 22;14(6):6878–6886. doi: 10.1021/acsnano.0c01007

Figure 4.

Figure 4.

GSI NP treatment improves HFD-induced glucose intolerance. (a) Experimental schematic. (b) GSI NPs reduce glucose excursion and (c) glucose area under the curve (AUC) after intraperitoneal glucose administration. (d) At sacrifice, GSI NPs reduced fasting blood glucose, without affecting (e) body weight, (f) body composition, or (g) liver and adipose tissue weights. (h) GSI NPs reduced Notch targets as well as expression of Foxo1 and its target genes with (i) commensurately reduced liver Foxo1 and p-Foxo1S256 levels. *p < 0.05, **p < 0.01 as compared to control NP-treated mice, n = 11–12/group.